 | Up a level |
Journal Article
Younes, Anas, Santoro, Armando 
ORCID: 0000-0003-1709-9492, Shipp, Margaret, Zinzani, Pier Luigi, Timmerman, John M., Ansell, Stephen, Armand, Philippe, Fanale, Michelle, Ratanatharathorn, Voravit, Kuruvilla, John, Cohen, Jonathon B., Collins, Graham ORCID: 0000-0002-8803-4234, Savage, Kerry J., Trneny, Marek ORCID: 0000-0002-6952-6073, Kato, Kazunobu, Farsaci, Benedetto ORCID: 0000-0001-8275-2561, Parker, Susan M., Rodig, Scott, Roemer, Margaretha G. M., Ligon, Azra H. and Engert, Andreas
(2016).
Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.
Lancet Oncol., 17 (9).
S. 1283 - 1295.
NEW YORK:
ELSEVIER SCIENCE INC.
ISSN 1474-5488
Younes, Anas, Santoro, Armando, Zinzani, Pier Luigi, Timmerman, John, Ansell, Stephen Maxted, Armand, Philippe, Fanale, Michelle A., Ratanatharathorn, Voravit, Kuruvilla, John, Cohen, Jonathon Brett, Collins, Graham P., Savage, Kerry J., Trneny, Marek, Kato, Kazunobu, Farsaci, Benedetto ORCID: 0000-0001-8275-2561, Parker, Susan M., Rodig, Scott J., Shipp, Margaret Ann and Engert, Andreas
(2016).
Checkmate 205: Nivolumab (nivo) in classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and brentuximab vedotin (BV) A phase 2 study.
J. Clin. Oncol., 34 (15).
ALEXANDRIA:
AMER SOC CLINICAL ONCOLOGY.
ISSN 1527-7755